Could Chewing Gum Help Block Oral HPV Linked to Cancer?

HPV vaccination programs have expanded to more than 100 countries, yet the incidence of oropharyngeal cancer, a cancer of the throat and tonsils strongly linked to HPV, has continued to rise even after vaccination became widespread. Investigators point to a key reason: HPV vaccines are injected into muscle and trigger a systemic immune response, but they don’t generate the local, mucosal antibodies needed to stop the virus from infecting or spreading through oral contact. That means someone can be fully vaccinated and still carry and transmit HPV through the mouth.

Globally, about one-third of men carry HPV, and roughly one-fifth carry HPV-16, the strain most strongly tied to cancer. Since oral HPV is largely driven by oral sex and spreads through direct mucosal contact, researchers say new tools are needed to reduce transmission and viral load at the source, in the mouth itself, rather than relying on vaccination alone.

Testing a Gum That Traps the Virus

A study published in Scientific Reports examined whether a chewing gum made with a bean-derived protein, called FRIL, could physically trap and neutralize HPV in the mouths of patients with head and neck cancer. FRIL works by binding to sugar structures on the surface of viruses, clumping virus particles together into large aggregates that can’t infect cells, a mechanism previously shown to work against influenza and coronavirus.

Investigators collected saliva and oral rinse samples from patients with head and neck cancer and cancer-free volunteers at two medical centers. HPV was detected in 100% of cancer patients’ saliva samples and about 75% of their oral rinse samples, a striking contrast to the far lower positivity rates seen in cancer-free participants.

A Sharp Drop in Viral Presence

When the bean-gum extract was applied to these samples, it aggregated and neutralized HPV in about 93% of saliva samples and 80% of oral rinse samples from patients with cancer. In many of those samples, aggregation was complete, ranging up to 100% viral clumping. The reduction was statistically significant across both sample types.

Because the assay measures the virus clumping together rather than being destroyed at the cellular level, the researchers note this shows how effectively FRIL traps and blocks HPV from functioning, though it doesn’t capture what happens once virus particles have already entered a person's cells.

A Two-For-One Approach

The same gum formulation was also combined with protegrin-1, a naturally occurring antimicrobial peptide, to target two bacteria strongly linked to oral cancer progression, Porphyromonas gingivalis and Fusobacterium nucleatum. That combination reduced both bacteria by more than 99% in a single treatment, while largely sparing beneficial bacteria that normally live in the mouth. Since HPV and these bacteria often coexist and may worsen outcomes together, tackling both with the same gum could offer a more complete approach than targeting the virus alone.

What Comes Next

This was an ex vivo study, meaning testing was done on collected saliva and oral rinse samples in a lab setting, not on a person’s mouth during normal use. The bean protein behind the gum has already been recognized as safe for use in food, and the gum formulation has been reviewed by the U.S. Food and Drug Administration (FDA) for other viral applications, which the investigators say supports moving toward actual clinical trials. For now, this remains early-stage research rather than an available treatment or HPV-prevention product, and it does not replace HPV vaccination, screening or standard cancer care.